P Palthera
Signalling Peptides

Pinealon

EDR / Glu-Asp-Arg

Pinealon is a short (Glu-Asp-Arg / EDR) developed by the Khavinson research group at the St Petersburg Institute of Bioregulation and Gerontology. Published evidence is — rodent and cell-culture studies — and is concentrated within the Khavinson network. There are no FDA, MHRA, or EMA approvals.

Add to comparison Subscribe
Abstract reference visual for Signalling Peptides.
Signalling Peptides
Classification
Khavinson short peptide · Glu-Asp-Arg tripeptide · Preclinical only
Research stage
Preclinical (rodent and cell-culture) literature from a single research network
Sequence
EDR (Glu-Asp-Arg)
Molecular weight
Approximately 418 Da

Snapshot

Key takeaways

A three-bullet snapshot before reading the full dossier.

  1. 01

    Short (Glu-Asp-Arg) developed by the Khavinson group.

  2. 02

    Published evidence is — rodent and cell-culture work.

  3. 03

    Peer-reviewed literature is concentrated within a single research network; independent replication is limited.

Dossier overview

3

research areas

2

references

3

handling notes

01

Mechanism of action

Cited work attributes Pinealon activity to short-peptide gene-regulatory effects in cerebellar neurons and pineal-derived cells. identity and have not been fully characterised in peer-reviewed literature outside the originating research network.

02

Research applications

  • Cerebellar granule-cell viability
  • Pineal-cell signalling-molecule expression studies
  • Rodent prenatal hyperhomocysteinemia models

Evidence at a glance

What's behind this profile

2 citations · 2011–2012

Animal
1

Studies in rodents or other animal models.

In vitro
1

Cell, tissue, or biochemical assays outside a living organism.

Publication years

  1. 11
  2. 12
20112012

Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 2 citations. Findings remain model-specific and are not extrapolated to therapeutic use.

03

Study references

Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.

Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes

2011

Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A · Rejuvenation Research

Model
In vitro — rat cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells
Sample
Not reported in abstract

Reported Pinealon was associated with reduced free-radical signal and altered viability metrics in cultured neurons and PC12 cells.

PMID 21978084 DOI 10.1089/rej.2011.1191

Pinealon protects the rat offspring from prenatal hyperhomocysteinemia

2012

Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V · International Journal of Clinical and Experimental Medicine

Model
In vivo — rat offspring exposed to prenatal hyperhomocysteinemia, with cerebellar neurons isolated from offspring
Sample
Not reported in abstract

Reported Pinealon administration reduced hyperhomocysteinemia-associated markers in rat offspring cerebellar tissue.

PMID 22803060

Evidence caveats

  • No controlled human trials indexed on PubMed at time of writing.
  • All cited primary evidence originates from the Khavinson research network in St Petersburg; independent replication is limited.
  • Findings are model-specific (rodent / cell-culture) and are not extrapolated to therapeutic use.

04

Storage and handling

Typically stored in a cool, dry environment under controlled laboratory conditions per supplier documentation.

  • Use supplier documentation for batch-specific handling.
  • Limit repeated cycles during research inventory handling.
  • Document date and storage condition where applicable.